Sandoz enters $265 million settlement agreement in U.S. price-fixing case

By Thomson Reuters Feb 29, 2024 | 12:26 AM

(Reuters) – Swiss generic and biosimilar manufacturer Sandoz on Thursday said it had entered into a $265 million settlement agreement in a price-fixing case in the United States.

The company said its U.S. subsidiaries had agreed to pay $265 million in a lawsuit with a class of direct drug purchasers, an agreement that does not contain any admission of wrongdoing by the Swiss company.

(Writing by Bartosz Dabrowski in Gdansk; Editing by Miranda Murray)